Identification of unique sensitizing targets for anti-inflammatory CDDO-Me in metastatic melanoma by a large-scale synthetic lethal RNAi screening

Pigment Cell and Melanoma Research

Volumn 26, Issue 1, 2013, Pages 97-112

  Qin, Yong ^a   Deng, Wuguo ^a   Ekmekcioglu, Suhendan ^a   Grimm, Elizabeth A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

CDDO Me; Drug target; Inflammation; Melanoma; Synthetic lethal siRNA screening

Indexed keywords

B RAF KINASE; BARDOXOLONE METHYL; BETA ACTIN; CASPASE 3; CASPASE 9; GLYCOGEN SYNTHASE KINASE; GLYCOGEN SYNTHASE KINASE 2; GLYCOGEN SYNTHASE KINASE 3ALPHA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; PROTEIN FLI1; PROTEIN GNPAT; PROTEIN KINASE B; PROTEIN PRAS40; PROTEIN SPINT2; PROTEIN SSX1; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CONTROL; CANCER INHIBITION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; FLI1 GENE; GENE; GNPAT GENE; HUMAN; HUMAN CELL; INFLAMMATION; MELANOMA CELL; METASTATIC MELANOMA; RNA INTERFERENCE; SCREENING; SIGNAL TRANSDUCTION; SPINT2 GENE; SUMO1 GENE; SXX1 GENE;

ANTI-INFLAMMATORY AGENTS; APOPTOSIS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENES, NEOPLASM; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MELANOMA; NEOPLASM METASTASIS; OLEANOLIC ACID; REPRODUCIBILITY OF RESULTS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84871429216     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12031     Document Type: Article

References (42)

1. Ahmad, R., Raina, D., Meyer, C., Kharbanda, S., and Kufe, D. (2006). Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179. J. Biol. Chem. 281, 35764-9.
2. Ahmad, R., Raina, D., Meyer, C., and Kufe, D. (2008). Triterpenoid CDDO-methyl ester inhibits the Janus-activated kinase-1 (JAK1)->signal transducer and activator of transcription-3 (STAT3) pathway by direct inhibition of JAK1 and STAT3. Cancer Res. 68, 2920-6.
3. Aza-Blanc, P., Cooper, C.L., Wagner, K., Batalov, S., Deveraux, Q.L., and Cooke, M.P. (2003). Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening. Mol. Cell 12, 627-37.
4. Berns, K., Hijmans, E.M., Mullenders, J. et al. (2004). A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature, 428, 431-437.
5. Collins, C.S., Hong, J., Sapinoso, L., Zhou, Y., Liu, Z., Micklash, K., Schultz, P.G., and Hampton, G.M. (2006). A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase. Proc. Natl Acad. Sci. USA 103, 3775-80.
6. Deeb, D., Gao, X., Dulchavsky, S.A., and Gautam, S.C. (2008). CDDO-Me inhibits proliferation, induces apoptosis, down-regulates Akt, mTOR, NF-kappaB and NF-kappaB-regulated antiapoptotic and proangiogenic proteins in TRAMP prostate cancer cells. J. Exp. Ther. Oncol. 7, 31-9.
7. Deeb, D., Gao, X., Jiang, H., Dulchavsky, S.A., and Gautam, S.C. (2009). Oleanane triterpenoid CDDO-Me inhibits growth and induces apoptosis in prostate cancer cells by independently targeting pro-survival Akt and mTOR. Prostate 69, 851-60.
8. Deng, W.G., Kawashima, H., Wu, G., Jayachandran, G., Xu, K., Minna, J.D., Roth, J.A., and Ji, L. (2007). Synergistic tumor suppression by coexpression of FUS1 and p53 is associated with down-regulation of murine double minute-2 and activation of the apoptotic protease-activating factor 1-dependent apoptotic pathway in human non-small cell lung cancer cells. Cancer Res. 67, 709-17.
9. Dressman, H.K., Berchuck, A., Chan, G. et al. (2007). An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J. Clin. Oncol. 25, 517-25.
10. Duan, Z., Ames, R.Y., Ryan, M., Hornicek, F.J., Mankin, H., and Seiden, M.V. (2009). CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells. Cancer Chemother. Pharmacol. 63, 681-9.
11. Ekmekcioglu, S., Ellerhorst, J.A., Prieto, V.G., Johnson, M.M., Broemeling, L.D., and Grimm, E.A. (2006). Tumor iNOS predicts poor survival for stage III melanoma patients. Int. J. Cancer 119, 861-866.
12. Gao, X., Deeb, D., Jiang, H., Liu, Y., Dulchavsky, S.A., and Gautam, S.C. (2007). Synthetic triterpenoids inhibit growth and induce apoptosis in human glioblastoma and neuroblastoma cells through inhibition of prosurvival Akt, NF-kappaB and Notch1 signaling. J. Neurooncol. 84, 147-57.
13. Han, J.Y., Lee, G.K., Yoo, S.Y., Yoon, S.J., Cho, E.Y., Kim, H.T., and Lee, J.S. (2010). Association of SUMO1 and UBC9 genotypes with tumor response in non-small-cell lung cancer treated with irinotecan-based chemotherapy. Pharmacogenomics J. 10, 86-93.
14. Hodge, D.R., Hurt, E.M., and Farrar, W.L. (2005). The role of IL-6 and STAT3 in inflammation and cancer. Eur. J. Cancer 41, 2502-12.
15. Hong, D.S., Kurzrock, R., Supko, J.G. et al. (2012). A phase i first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin. Cancer Res. 18, 3396-406.
16. Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., and Thun, M.J. (2007). Cancer statistics, 2007. CA Cancer J. Clin. 57, 43-66.
17. Konopleva, M., Tsao, T., Ruvolo, P. et al. (2002). Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood 99, 326-35.
18. Konopleva, M., Contractor, R., Kurinna, S.M., Chen, W., Andreeff, M., and Ruvolo, P.P. (2005). The novel triterpenoid CDDO-Me suppresses MAPK pathways and promotes p38 activation in acute myeloid leukemia cells. Leukemia 19, 1350-4.
19. La Porta, C.A. (2007). Drug resistance in melanoma: new perspectives. Curr. Med. Chem. 14, 387-91.
20. Liu, D., Nagan, N., Just, W.W., Rodemer, C., Thai, T.P., and Zoeller, R.A. (2005). Role of dihydroxyacetonephosphate acyltransferase in the biosynthesis of plasmalogens and nonether glycerolipids. J. Lipid Res. 46, 727-35.
21. Mackeigan, J.P., Murphy, L.O., and Blenis, J. (2005). Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat. Cell Biol. 7, 591-600.
22. Moretti, S., Pinzi, C., Spallanzani, A., Berti, E., Chiarugi, A., Mazzoli, S., Fabiani, M., Vallecchi, C., and Herlyn, M. (1999). Immunohistochemical evidence of cytokine networks during progression of human melanocytic lesions. Int. J. Cancer 84, 160-168.
23. Nagaraj, S., Youn, J.I., Weber, H. et al. (2010). Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin. Cancer Res. 16, 1812-23.
24. Ngo, V.N., Davis, R.E., Lamy, L. et al. (2006). A loss-of-function RNA interference screen for molecular targets in cancer. Nature 441, 106-10.
25. Pergola, P.E., Raskin, P., Toto, R.D. et al. (2011). Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N. Engl. J. Med. 365, 327-36.
26. Petronelli, A., Pannitteri, G., and Testa, U. (2009). Triterpenoids as new promising anticancer drugs. Anticancer Drugs 20, 880-92.
27. Qin, Y., Ekmekcioglu, S., Liu, P., Duncan, L.M., Lizee, G., Poindexter, N., and Grimm, E.A. (2011). Constitutive aberrant endogenous interleukin-1 facilitates inflammation and growth in human melanoma. Mol. Cancer Res. 9, 1537-50.
28. Raslova, H., Komura, E., Le Couedic, J.P., Larbret, F., Debili, N., Feunteun, J., Danos, O., Albagli, O., Vainchenker, W., and Favier, R. (2004). FLI1 monoallelic expression combined with its hemizygous loss underlies Paris-Trousseau/Jacobsen thrombopenia. J. Clin. Invest. 114, 77-84.
29. Rass, K., and Hassel, J.C. (2009). Chemotherapeutics, chemoresistance and the management of melanoma. G. Ital. Dermatol. Venereol. 144, 61-78.
30. Rottmann, S., Wang, Y., Nasoff, M., Deveraux, Q.L., and Quon, K.C. (2005). A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3beta/FBW7 loss of function. Proc. Natl Acad. Sci. USA 102, 15195-200.
31. Shishodia, S., Sethi, G., Konopleva, M., Andreeff, M., and Aggarwal, B.B. (2006). A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells. Clin. Cancer Res. 12, 1828-38.
32. Sikora, A.G., Gelbard, A., Davies, M.A. et al. (2010). Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin. Cancer Res. 16, 1834-44.
33. Tang, C.H., and Grimm, E.A. (2004). Depletion of endogenous nitric oxide enhances cisplatin-induced apoptosis in a p53-dependent manner in melanoma cell lines. J. Biol. Chem. 279, 288-298.
34. Taylor, B.J., Reiman, T., Pittman, J.A., Keats, J.J., De Bruijn, D.R., Mant, M.J., Belch, A.R., and Pilarski, L.M. (2005). SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs. J. Immunother. 28, 564-75.
35. Thimmulappa, R.K., Fuchs, R.J., Malhotra, D. et al. (2007). Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils. Antioxid. Redox Signal. 9, 1963-70.
36. Toub, N., Bertrand, J.R., Tamaddon, A., Elhamess, H., Hillaireau, H., Maksimenko, A., Maccario, J., Malvy, C., Fattal, E., and Couvreur, P. (2006). Efficacy of siRNA nanocapsules targeted against the EWS-Fli1 oncogene in Ewing sarcoma. Pharm. Res. 23, 892-900.
37. Tran, K., Risingsong, R., Royce, D., Williams, C.R., Sporn, M.B., and Liby, K. (2012). The synthetic triterpenoid CDDO-methyl ester delays estrogen receptor-negative mammary carcinogenesis in polyoma middle T mice. Cancer Prev. Res. (Phila) 5, 726-34.
38. Uffort, D.G., Grimm, E.A., and Ellerhorst, J.A. (2009). NF-kappaB mediates mitogen-activated protein kinase pathway-dependent iNOS expression in human melanoma. J. Invest. Dermatol. 129, 148-154.
39. Wang, S., Liu, Z., Wang, L., and Zhang, X. (2009). NF-kappaB signaling pathway, inflammation and colorectal cancer. Cell. Mol. Immunol. 6, 327-34.
40. Westbrook, T.F., Martin, E.S., Schlabach, M.R. et al. (2005). A genetic screen for candidate tumor suppressors identifies REST. Cell 121, 837-48.
41. Yancy, H.F., Mason, J.A., Peters, S., Thompson, C.E. 3rd, Littleton, G.K., Jett, M., and Day, A.A. (2007). Metastatic progression and gene expression between breast cancer cell lines from African American and Caucasian women. J. Carcinog. 6, 8.
42. Zhang, J.H., Chung, T.D., and Oldenburg, K.R. (1999). A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J. Biomol. Screen. 4, 67-73.